AN2 Therapeutics annual operating expenses
2021
2022
2023
2024
2025
AN2 Therapeutics Operating Expenses Growth & History (ANTX)
AN2 Therapeutics's operating expenses was $38.1M for fiscal 2025.
View full AN2 Therapeutics company overviewAN2 Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $38.1M | −$18.7M | −32.89% |
| 2024 | 2024-12-31 | $56.8M | −$12.8M | −18.45% |
| 2023 | 2023-12-31 | $69.6M | $27.4M | +64.77% |
| 2022 | 2022-12-31 | $42.3M | $20.7M | +95.89% |
| 2021 | 2021-12-31 | $21.6M | — | — |
AN2 Therapeutics quarterly operating expenses
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.9M | $1.7M | +23.39% |
| Q1 2026 | 2026-03-31 | $10.6M | −$986,000 | −8.55% |
| Q4 2025 | 2025-12-31 | $9.3M | $718,000 | +8.35% |
| Q3 2025 | 2025-09-30 | $10.0M | −$4.0M | −28.36% |
| Q2 2025 | 2025-06-30 | $7.2M | −$8.7M | −54.56% |
| Q1 2025 | 2025-03-31 | $11.5M | −$6.8M | −36.94% |
| Q4 2024 | 2024-12-31 | $8.6M | −$10.2M | −54.30% |
| Q3 2024 | 2024-09-30 | $14.0M | −$4.2M | −22.92% |
| Q2 2024 | 2024-06-30 | $15.9M | −$721,000 | −4.34% |
| Q1 2024 | 2024-03-31 | $18.3M | $2.3M | +14.07% |
| Q4 2023 | 2023-12-31 | $18.8M | $6.3M | +50.81% |
| Q3 2023 | 2023-09-30 | $18.2M | $6.4M | +54.46% |
| Q2 2023 | 2023-06-30 | $16.6M | $6.3M | +60.66% |
| Q1 2023 | 2023-03-31 | $16.0M | $8.4M | +108.76% |
| Q4 2022 | 2022-12-31 | $12.5M | $4.9M | +64.29% |
| Q3 2022 | 2022-09-30 | $11.8M | $4.8M | +69.79% |
| Q2 2022 | 2022-06-30 | $10.3M | $5.3M | +106.74% |
| Q1 2022 | 2022-03-31 | $7.7M | $5.6M | +274.78% |
| Q4 2021 | 2021-12-31 | $7.6M | — | — |
| Q3 2021 | 2021-09-30 | $6.9M | — | — |
| Q2 2021 | 2021-06-30 | $5.0M | — | — |
| Q1 2021 | 2021-03-31 | $2.0M | — | — |
AN2 Therapeutics operating expenses trends
Between the periods ended 2021-12-31 and 2025-12-31, AN2 Therapeutics's operating expenses increased from $21.6M to $38.1M, a change of $16.5M. The latest reported quarter, Q2 2026, shows $8.9M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AN2 Therapeutics source filings ↗